[DOI] [PubMed] [Google Scholar] McClean PL, Hlscher C
Semaglutide's mechanism involves slowing gastric emptying, enhancing glucose-dependent insulin secretion, and reducing appetite through central nervous system pathways
Given its strong weight-loss performance, Orforglipron is expected to capture a meaningful share of this expanding market
[10] [11] Phase 2 trial data published in the New England Journal of Medicine in 2023 (Jastreboff et al.) demonstrated substantial effects on body weight and metabolic parameters, though the full benefitrisk profile is still being established in ongoing Phase 3 trials
Infections are common culprits, with tuberculosis and HIV being classic examples, though various bacterial, viral, and fungal infections can cause night sweats
The American Heart Association and the Heart Failure Society of America note that GLP-1R agonists can decrease systemic inflammation and platelet aggregation, contributing to their cardiovascular benefits [101]